Robert Decker, MD
Hematology & Oncology · Hazleton, PANPI 1114452935
Payments from drug & device makers
What this record shows
This record is dominated by education: $753 of the $838 with a category attached, or 89.9%. 6 manufacturers reported payments, led by Incyte Corporation at 33.4% of the total. Reporting peaked in 2023 at $223 and has fallen 61.9% since, to $85 in 2024. That places this record below the midpoint for hematology & oncology clinicians in PA, where the typical reported total is $1,277.
Across 9 payments — averaging $93.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$280
- Johnson & Johnson$151
- Lilly USA, LLC$123
- Gilead$100
- Seagen Inc.$100
- Tempus AI, Inc$85
What the payments were for
- Food & beverage$8510%
- Education$75390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 3 | $280 |
| Johnson & Johnson | 2 | $151 |
| Lilly USA, LLC | 1 | $123 |
| Gilead | 1 | $100 |
| Seagen Inc. | 1 | $100 |
| Tempus AI, Inc | 1 | $85 |
How this compares
$838 in reported general payments places this provider in the 40th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AlecensaAlectinib Hcl | 15 | $279,485 |
| BraftoviEncorafenib | 11 | $176,733 |
| Abiraterone Acetate | 47 | $81,372 |
| EliquisApixaban | 19 | $20,357 |
| Fentanyl | 23 | $3,638 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 33 | $1,839 |
| Letrozole | 63 | $1,220 |
| Dexamethasone | 132 | $1,210 |
| Prochlorperazine Maleate | 119 | $1,206 |
| Oxycodone Hcl | 43 | $857 |
| Hydroxyurea | 20 | $718 |
| Morphine Sulfate ErMorphine Sulfate | 12 | $336 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 24 | $326 |
| Lorazepam | 42 | $237 |
| Acyclovir | 26 | $229 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Hazleton
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Usama GergisAllentown$1.2M
- Kit LuHarrisburg$810K
- Henry FungPhiladelphia$730K
- Alexander BarsoukPittsburgh$674K
- Abdalla SholiWilliamsport$576K
- Charu AggarwalPhiladelphia$541K
- Tracey EvansEast Norriton$500K
- Corey LangerPhiladelphia$492K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.